English

NORDIC NANOVECTOR ASA – MANDATORY NOTIFICATION OF TRADE/ISSUANCE OF NEW SHARES

Report this content

 

Rita Dege, Chief Human Resources Officer has exercised 3,000 options in Nordic Nanovector ASA (the "Company"), corresponding to 3,000 shares at a strike price of NOK 28 per share. The board of directors of the Company has pursuant to the authorisation granted to board of directors at the annual general meeting in 2016, resolved to issue 3,000 new shares at a subscription price of NOK 28 per share to Rita Dege. The Company will following the issuance of the new shares have a share capital of NOK 8,920,074.80 divided on 44,600,374 shares, each with a nominal value of NOK 0.20 per share.

After the exercise of the options, Rita Dege owns 3,000 shares in the Company and Rita Dege holds 32,000 options in the Company.

This information is subject to duty of disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act and section 3.2 of the Continuing Obligations listed companies.

 

 

Tags:

Cancer Therapy non-hodgkins lymphoma Betalutin Nordic Nanovector Radioimmunotherapy Roy Hartvig Larsen anticancer therapeutics

Subscribe